Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 78 citing Campbell: Medicare program expenditures associated with hospice use. (0.13 sec) 

Pharmacogenomics in Alzheimer's disease


R Cacabelos - Methods Mol Biol, 2008 - Springer
Summary Pharmacological treatment in Alzheimer's disease (AD) accounts for
10–20% of direct costs, and fewer than 20% of AD patients are moderate
responders to conventional drugs (donepezil, rivastigmine, galantamine, ...
Cited by 49 - Related articles - All 8 versions

Why do patients choose chemotherapy near the end of life? A review of the perspective of …

- ascopubs.org
R Matsuyama, S Reddy, TJ Smith - Journal of Clinical Oncology, 2006 - jco.ascopubs.org
RESULTS: Available patient sources provide little information about prognosis,
choices, alternatives, consequences, or how to choose. Many patients would
choose chemotherapy for a small benefit in health outcomes, and for a ...
Cited by 44 - Related articles - All 7 versions

Medicare cost in matched hospice and non-hospice cohorts


B Pyenson, S Connor, K Fitch, B Kinzbrunner - Journal of pain and symptom management, 2004 - Elsevier
Hospice care is perceived as enhancing life quality for patients with advanced,
incurable illness, but cost comparisons to non-hospice patients are difficult to
make. The very large Medicare expenditures for care given during the end of ...
Cited by 39 - Related articles - All 3 versions

Hospice and palliative care in nursing homes


SC Miller, JM Teno, V Mor - Clinics in geriatric medicine, 2004 - Elsevier
Nursing homes have become a common site of death. In some states, more than one
in three deaths now occur in nursing homes [1], but in the 1990s, only one in
five deaths occurred in nursing homes. This striking change in site of ...
Cited by 36 - Related articles - All 12 versions

Hospice care for heart failure patients

- uchsc.edu [PDF] 
SJ Goodlin, JS Kutner, SR Connor, T Ryndes … - Journal of pain and symptom management, 2005 - Elsevier
Although approximately 260,000 persons die annually in the United States (USA)
with heart failure (HF), HF patients infrequently receive hospice care. Patients
with refractory symptoms of HF at rest despite optimal medical therapy ...
Cited by 29 - Related articles - All 4 versions

What length of hospice use maximizes reduction in medical expenditures near death in …

- votivahealth.com [PDF] 
DH Taylor, J Ostermann, CH Van Houtven, JA … - Social Science & Medicine, 2007 - Elsevier
Hospices have been expected to reduce health expenditures since their addition
to the US Medicare benefit package in the early-1980s, but the literature on
their ability to do so is mixed. The contradictory findings noted in ...
Cited by 25 - Related articles - All 14 versions

Effects of a program for coordinated care of advanced illness on patients, surrogates, and …


JB Engelhardt, KP McClive-Reed, RW … - Am J Manag Care, 2006 - ajmc.com
Objective: To evaluate the Advanced Illness Coordinated Care Program (AICCP),
delivered by allied health personnel to improve care for patients coping with
advanced illness and in need of preparation for end-of-life (EOL) care.
Cited by 18 - Related articles - Cached - All 5 versions

End-of-life care: an agenda for policy improvement


LR Shugarman, K Lorenz, J Lynn - Clinics in geriatric medicine, 2005 - Elsevier
Health care in the United States has not adequately addressed the needs of a
growing population with serious, eventually fatal chronic illness. In 1982,
legislation established Medicare hospice, although experience and research ...
Cited by 16 - Related articles - All 18 versions

Trends in End-of-Life ICU Use Among Older Adults With Advanced Lung Cancer*

- chestpubs.org
G Sharma, J Freeman, D Zhang, JS Goodwin - Chest, 2008 - chestjournal.chestpubs.org
Results: ICU use in the last 6 months of life increased from 17.5% in 1993 to
24.7% in 2002 (p < 0.001). After adjusting for patient characteristics, there
was a 6.6% annual increase in ICU use from 1993 to 2002. During the same ...
Cited by 15 - Related articles - BL Direct - All 9 versions

Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease


R Cacabelos, M Takeda - Drugs Future, 2006 - journals.prous.com
Abstract Alzheimer's disease (AD) is a major health problem in developed
countries, representing an important socioeconomic burden for the community.
Approximately, 10% of the direct costs of AD are attrib- uted to ...
Cited by 11 - Related articles - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google